Tonix Pharmaceuticals stock halted ahead of FDA approval news
Link Ventures LLLP, a ten percent owner of EverQuote , Inc. (NASDAQ:EVER), sold 900,000 shares of Class A Common Stock on August 10, 2025, for $23.33 per share, totaling $20,997,000. The transaction comes as EverQuote demonstrates strong financial health, with InvestingPro analysis showing robust revenue growth of 93% over the last twelve months and a healthy current ratio of 3.03.
Following the transaction, Link Ventures directly owns 2,598,154 shares of EverQuote. The sale was executed under a Stock Repurchase Agreement between Link Ventures and EverQuote. According to InvestingPro data, the stock currently trades below its Fair Value, with analysts setting price targets between $29 and $38 per share. Additional insights and detailed analysis are available in EverQuote’s comprehensive Pro Research Report, one of 1,400+ deep-dive reports available on InvestingPro.
Link Management, LLC, the general partner of Link Ventures, LLLP, also reported the transaction. The company maintains a strong market position with a market capitalization of $856 million and has received positive analyst revisions for the upcoming period.
In other recent news, EverQuote Inc. reported substantial revenue growth in its second-quarter earnings, with total revenues rising 34% year-over-year to $156.6 million. The company also achieved a record net income of $14.7 million, a significant increase from the previous year’s $6.4 million. This financial performance marks a notable development for the company. Additionally, EverQuote announced it has agreed to repurchase 900,000 shares of its Class A common stock for $21 million from entities affiliated with Chairman and Co-Founder David Blundin. This transaction was executed at $23.33 per share, representing a discount to recent price averages. In analyst updates, JPMorgan has reduced its price target on EverQuote to $29 from $30, citing concerns about how tariffs might impact the company’s margins in the second half of the year. Despite this, JPMorgan maintains an Overweight rating on the company. These developments reflect a dynamic period for EverQuote as it navigates market conditions and strategic financial decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.